There is an increasing amount of evidence supporting the pivotal role of ADMA, an endogenous NOS inhibitor, in a large number of disorders characterized by endothelial dysfunction [5], [22]–[24]. The gene discussed is NOS1; the disease is endothelial dysfunction.